Project Description

A novel drug for osteoporosis

Targeting of specific  membrane receptors may result in potential therapeutic effects in several types of clinical conditions. Our researchers at NTNU have demonstrated novel inhibitors to efficiently and selectively inhibit signaling of a receptor that may be relevant for control of bone re-modelling .

We put forward to optimize these novel drug leads and perform pre-clinical studies with the ideal goal of approaching major pharma-companies for clinical trials.